Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Enveric Biosciences ( (ENVB) ) is now available.
On January 27, 2026, Enveric Biosciences entered into securities purchase agreements with institutional investors for a $1.5 million capital raise via a registered direct offering of 328,802 common shares at $4.41 per share, which closed on January 28, 2026. Concurrently, in a private placement that also closed on January 28, 2026, the company issued Series G and Series H common stock warrants covering up to 657,604 shares in total, alongside additional warrants to placement agent H.C. Wainwright & Co., with customary anti-dilution protections and beneficial ownership caps. Net proceeds of approximately $1.25 million are earmarked for product development, working capital and general corporate purposes, providing incremental funding for Enveric’s R&D pipeline while modestly diluting existing shareholders and temporarily restricting further equity issuance for 15 days following the transaction.
The most recent analyst rating on (ENVB) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Enveric Biosciences stock, see the ENVB Stock Forecast page.
Spark’s Take on ENVB Stock
According to Spark, TipRanks’ AI Analyst, ENVB is a Neutral.
The score is held down primarily by weak financial performance (no revenue, continued losses and cash burn) and bearish technicals (price far below key moving averages with negative MACD). Corporate events provide some offset via fresh funding and regained Nasdaq compliance, but valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on ENVB stock, click here.
More about Enveric Biosciences
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics to address unmet needs in psychiatric and neurological disorders. Leveraging a proprietary drug discovery platform and a growing library of patent-protected chemical structures, the company is advancing a pipeline of non-hallucinogenic compounds designed to promote neuroplasticity, led by EB-003, a dual 5-HT2A/5-HT1B receptor modulator intended to deliver fast-acting, durable antidepressant and anxiolytic effects suitable for outpatient use.
Average Trading Volume: 732,039
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.26M
For an in-depth examination of ENVB stock, go to TipRanks’ Overview page.